Xenon Pharmaceuticals Inc.
XENE· Nasdaq
XENEXenon Pharmaceuticals Inc.
Filed Mar 1, 2021 · 10-K · 60 days after period end · 0001564590-21-009905
derived · Computed from the longer spans the company filed.
| Metric | Q4 2020dderived from reported figures | Q4 2019dderived from reported figures | Q4 2018dderived from reported figures | Q4 2017 |
|---|---|---|---|---|
| Revenue | $5.15M | — | — | $16.00K |
| Net Income | -$12.32M | -$11.38M | -$8.56M | -$8.07M |
| EPS Diluted | — | — | — |
Xenon Pharmaceuticals Inc. · CIK 1582313 · Engraved from SEC EDGAR
| -$0.45 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
ended Dec 31, 2020 · filed Mar 1, 2021 · 60 d after period end
